

Drug Monograph

Drug/Drug **Aczone[®] (dapsonsone) gel/ Topical Acne Products**

Class:

Prepared for: MO HealthNet

Prepared by: Xerox Heritage, LLC

New Criteria

Revision of Existing Criteria

Executive Summary

Purpose:	The purpose of this monograph is to provide a review of new therapy to determine whether the reviewed drug should be made available on an open access basis to prescribers, require a clinical edit or require prior authorization for use.	
Dosage Forms:	Aczone [®] is now available in a 7.5% gel that contains 75 mg of dapsonsone per gram.	
Manufacturer:	Allergan, Inc., Irvine CA 92612	
Indications:	Aczone [®] is indicated for the topical treatment of acne vulgaris in patients 12 years of age and older.	
Costs:	\$8.25 per gram of Aczone [®] . Wholesale Acquisition Cost	
Summary of Findings:	The MO HealthNet Division recommends prior authorization status for this product.	
Status Recommendation:	<input checked="" type="checkbox"/> Prior Authorization (PA) Required <input type="checkbox"/> Fiscal Edit	<input type="checkbox"/> Open Access <input type="checkbox"/> PDL
Type of PA Criteria:	<input type="checkbox"/> Increased Risk of ADE <input checked="" type="checkbox"/> Appropriate Indications	<input type="checkbox"/> Under Solicitation <input type="checkbox"/> No PA Required

Prepared By: Luke Boehmer Pharm.D.
Date: August 11, 2016